Program
brimonidine
Also written as “Brimonidine”, “Brimonidine Tartrate” and “CD07805/47 Gel”.
Its studies are mostly in Glaucoma · Rosacea · Glaucoma, Open-Angle · Conjunctivitis, Allergic · Hyperemia, led by 10 companies.
Drug pageBrimonidine: every studyMany companies study it; this page follows only the 52 they lead. All 104 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 220 open or running | phase 4since Apr 6, 2007 | Sep 12, 2005 | none ahead |
| Galderma Groupits history only | 100 open or running | phase 4since Sep 23, 2014 | Jun 12, 2008 | none ahead |
| Bausch Health Companiesits history only | 70 open or running | phase 3since Oct 8, 2013 | Oct 8, 2013 | none ahead |
| Eye Therapiesits history only | 30 open or running | phase 2since Jan 10, 2011 | Jan 10, 2011 | none ahead |
| Ocugenits history only | 30 open or running | phase 3since Jul 9, 2018 | Oct 10, 2017 | none ahead |
| Alconits history only | 20 open or running | phase 4since Dec 1, 2008 | May 28, 2003 | none ahead |
| Tarian Pharmaits history only | 22 open or running | phase 2since Jan 23, 2025 | Jan 23, 2025 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Oct 1, 2015 | Oct 1, 2015 | none ahead |
| Innovative Medicalits history only | 10 open or running | phase 4since Jun 30, 2006 | Jun 30, 2006 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Oct 31, 2014 | Oct 31, 2014 | none ahead |
Also a collaborator on its studies: ORA and Eurotrials Brasil Consultores Cientificos Ltda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Sep 12, 2005.
- Apr 1, 20082 phase 3 studies in GlaucomaNCT00652483, NCT00651612
- Apr 11, 2008Phase 2 study in Macular DegenerationNCT00658619 · 119 enrolled · United States, Australia, Germany and more
- Jun 5, 2008Phase 2 study in Glaucoma, Open-AngleNCT00693485 · 70 enrolled · United States, Israel
- Jan 13, 2009Phase 4 study in Glaucoma, Open-AngleNCT00822055 · 140 enrolled · Canada
- Sep 3, 2009Phase 2 study in Rhegmatogenous Macula-off Retinal DetachmentNCT00972374 · 44 enrolled · United States, India, Israel and more
- Jun 5, 2010Phase 4 study in Glaucoma, Angle-ClosureNCT01151904 · 17 enrolled · Thailand
- Oct 6, 20102 phase 3 studiesNCT01216943, NCT01217606
- Oct 20, 2010Phase 1 study in VitrectomyNCT01229410 · 24 enrolled · United States, Czech Republic
- Oct 26, 2010No phase study in GlaucomaNCT01229462 · 238 enrolled · China
- Nov 12, 2010Phase 3 study in Glaucoma, Open-AngleNCT01241240 · 192 enrolled · Colombia, Mexico
- Jan 31, 2012Phase 4 study in GlaucomaNCT01525173 · 137 enrolled · United States
- May 24, 2013Phase 2 study in GlaucomaNCT01863953 · 112 enrolled · United States
- Dec 2, 2013Phase 4 study in Glaucoma, Open-AngleNCT02003534 · 376 enrolled · China
- Mar 12, 2014Phase 2 study in Geographic AtrophyNCT02087085 · 310 enrolled · United States, Australia, France and more
TargetBeta
“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexmedetomidinerule | Pfizer | phase 4 | 46 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| tizanidinerule | Teva Pharmaceutical Industries | phase 4 | 11 |
| Clonidinerule | pharmafina | phase 4 | 5 |
| lofexidinerule | uswm-llc-dba-us-worldmeds | phase 3 | 15 |
Studies
All 22 AbbVie leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02087085Geographic Atrophy · United States, Australia, France and more | 2 | Terminated | Mar 30, 2018 | 310 |
| NCT02003534Glaucoma, Open-Angle · China | 4 | Completed | Feb 2013 | 376 |
| NCT01863953Glaucoma · United States | 2 | Completed | Dec 2013 | 112 |
| NCT01525173Glaucoma · United States | 4 | Completed | Oct 2012 | 137 |
| NCT01241240Glaucoma, Open-Angle · Colombia, Mexico | 3 | Completed | Sep 2013 | 192 |
| NCT01229462Glaucoma · China | – | Completed | Sep 2011 | 238 |
| NCT01229410Vitrectomy · United States, Czech Republic | 1 | Completed | May 2011 | 24 |
| NCT01217606Glaucoma, Open-Angle · Brazil | 3 | Completed | Sep 2014 | 185 |
| NCT01216943Glaucoma · India | 3 | Completed | Aug 2012 | 126 |
| NCT01151904Glaucoma, Angle-Closure · Thailand | 4 | Terminated | Feb 2012 | 17 |
| NCT00972374Rhegmatogenous Macula-off Retinal Detachment · United States, India, Israel and more | 2 | Completed | Oct 2010 | 44 |
| NCT00822055Glaucoma, Open-Angle · Canada | 4 | Completed | Nov 2006 | 140 |
| NCT00693485Glaucoma, Open-Angle · United States, Israel | 2 | Completed | Jan 2011 | 70 |
| NCT00658619Macular Degeneration · United States, Australia, Germany and more | 2 | Completed | Jun 1, 2010 | 119 |
| NCT00652483Glaucoma · United States | 3 | Completed | Dec 2003 | 433 |
| NCT00651612Glaucoma · United States | 3 | Completed | Jan 2007 | 604 |
| NCT00661479Retinitis Pigmentosa · United States, France, Germany and more | 2 | Completed | Dec 2009 | 21 |
| NCT00457795Glaucoma, Open-Angle · United States | 4 | Completed | Feb 2009 | 15 |
| NCT00332436Ocular Hypertension · United States | 3 | Completed | Nov 2001 | 586 |
| NCT00332384Ocular Hypertension · United States | 3 | Completed | Nov 2001 | 573 |
| NCT00332345Ocular Hypertension · United States | 2 | Completed | Aug 1999 | 73 |
| NCT00168363Glaucoma | 3 | Completed | Aug 2006 | 207 |
How it is read
Names in the registry
- “Brimonidine”, 4 entries
- “Brimonidine Tartrate”, 4 entries
- “CD07805/47 Gel”, 4 entries
- “CD07805/47”, 3 entries
- “400 µg Brimonidine Tartrate Implant”, 3 entries
Conditions, from the studies’ own filings
- Glaucoma, 10 studies
- Rosacea, 9 studies
- Glaucoma, Open-Angle, 8 studies
- Conjunctivitis, Allergic, 4 studies
- Hyperemia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.